CA2949579A1 - A liquid formulation comprising nicotine for aerosol administration - Google Patents
A liquid formulation comprising nicotine for aerosol administration Download PDFInfo
- Publication number
- CA2949579A1 CA2949579A1 CA2949579A CA2949579A CA2949579A1 CA 2949579 A1 CA2949579 A1 CA 2949579A1 CA 2949579 A CA2949579 A CA 2949579A CA 2949579 A CA2949579 A CA 2949579A CA 2949579 A1 CA2949579 A1 CA 2949579A1
- Authority
- CA
- Canada
- Prior art keywords
- liquid formulation
- percent
- weight
- nicotine
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012669 liquid formulation Substances 0.000 title claims abstract description 84
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 70
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960002715 nicotine Drugs 0.000 title claims abstract description 69
- 239000000443 aerosol Substances 0.000 title claims abstract description 52
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 70
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 230000003287 optical effect Effects 0.000 claims description 17
- 238000009835 boiling Methods 0.000 claims description 13
- 238000004891 communication Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 41
- 239000000203 mixture Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- FXFANIORDKRCCA-UHFFFAOYSA-N Norcotinine Chemical compound N1C(=O)CCC1C1=CC=CN=C1 FXFANIORDKRCCA-UHFFFAOYSA-N 0.000 description 6
- DPNGWXJMIILTBS-UHFFFAOYSA-N myosmine Chemical compound C1CCN=C1C1=CC=CN=C1 DPNGWXJMIILTBS-UHFFFAOYSA-N 0.000 description 6
- 235000019504 cigarettes Nutrition 0.000 description 5
- 230000000391 smoking effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MYKUKUCHPMASKF-SECBINFHSA-N (+)-Nornicotine Chemical compound C1CCN[C@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-SECBINFHSA-N 0.000 description 3
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 229950006073 cotinine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- RWFBQHICRCUQJJ-JQWIXIFHSA-N trans-(S)-nicotine N(1')-oxide Chemical compound C[N@+]1([O-])CCC[C@H]1C1=CC=CN=C1 RWFBQHICRCUQJJ-JQWIXIFHSA-N 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- FFYVQVZXWDGRAY-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;hydrate Chemical compound O.CN1CCCC1C1=CC=CN=C1 FFYVQVZXWDGRAY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100065878 Caenorhabditis elegans sec-10 gene Proteins 0.000 description 1
- 101100065885 Caenorhabditis elegans sec-15 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- -1 patches Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- QMYDVDBERNLWKB-UHFFFAOYSA-N propane-1,2-diol;hydrate Chemical compound O.CC(O)CO QMYDVDBERNLWKB-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/10—Devices using liquid inhalable precursors
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F47/00—Smokers' requisites not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
In one aspect, the present invention features a method of administering nicotine or a salt thereof to a human, wherein the method includes inhaling an aerosol of a liquid formulation, the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol. The present invention also features an aerosol-generating device and a reservoir for such a device containing such a liquid formulation.
Description
A LIQUID FORMULATION COMPRISING NICOTINE
FOR AEROSOL ADMINISTRATION
Background of the Invention Over the years, various types of products have been developed, as an alternative means to smoking, to administer nicotine to a user to aid in smoking cessation (e.g., gums, lozenges, patches, nasal sprays, mouth sprays, and inhalators). For certain drugs, inhalation is considered as an efficacious route of administration due to the rapid absorption of the drug and avoidance of the first pass effect. For such drugs, a high plasma level can be achieved rapidly after inhalation of aerosol formulations. In the case of nicotine replacement therapy, it is believed that a rapid and sufficiently high nicotine plasma levels in the body is of high importance as tobacco smoking also delivers nicotine to the body in the form of inhalable aerosols.
Recently, e-cigarettes, electronic inhalators designed to look like a cigarette that generates aerosols usually containing nicotine, have become popular. These devices mimic the look and feel of a cigarette, but claim to avoid the dangers associated with inhaling burned tobacco smoke. In order to mimic cigarette smoke, these electronic inhalers often utilize liquid formulations (often containing glycerol) that, upon use, create aerosols that, like tobacco smoke, are visible upon exhalation by the user.
Although, many e-cigarettes formulations contain nicotine, their use as a means to quit smoking can be inadequate for various reasons, such as: (i) the nicotine concentration in the formulation can be too low, (ii) a considerable amount of nicotine can be lost by not being captured by the body, and (iii) given the visible aerosol they often generate, their use is not discreet and mimics the habit that the user desires to quit. Thus, there is a need to develop liquid formulation containing a high concentration of nicotine whose generated aerosol is less visible and is better retained in the oral and respiratory tracts.
Summary of the Invention In one aspect, the present invention features a method of administering nicotine or a salt thereof to a human, wherein the method includes inhaling an aerosol of a liquid formulation, the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol.
In another aspect, the present invention features an aerosol-generating device comprising a reservoir containing a liquid formulation, wherein the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof;
wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol and wherein the aerosol-generating device is arranged and configured to generate an aerosol of said liquid formulation.
io In still another aspect, the present invention features a reservoir containing a liquid formulation, wherein the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol and wherein the reservoir is arranged and configured to attach to an aerosol-generating device to provide fluid communication for such liquid formulation from the reservoir to the aerosol- generating device.
Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims.
Detailed Description of the Invention It is believed that one skilled in the art can, based upon the description herein, utilizes the present invention to its fullest extent. The following specific embodiments can be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. As used herein, all percentages are by weight unless otherwise specified.
FOR AEROSOL ADMINISTRATION
Background of the Invention Over the years, various types of products have been developed, as an alternative means to smoking, to administer nicotine to a user to aid in smoking cessation (e.g., gums, lozenges, patches, nasal sprays, mouth sprays, and inhalators). For certain drugs, inhalation is considered as an efficacious route of administration due to the rapid absorption of the drug and avoidance of the first pass effect. For such drugs, a high plasma level can be achieved rapidly after inhalation of aerosol formulations. In the case of nicotine replacement therapy, it is believed that a rapid and sufficiently high nicotine plasma levels in the body is of high importance as tobacco smoking also delivers nicotine to the body in the form of inhalable aerosols.
Recently, e-cigarettes, electronic inhalators designed to look like a cigarette that generates aerosols usually containing nicotine, have become popular. These devices mimic the look and feel of a cigarette, but claim to avoid the dangers associated with inhaling burned tobacco smoke. In order to mimic cigarette smoke, these electronic inhalers often utilize liquid formulations (often containing glycerol) that, upon use, create aerosols that, like tobacco smoke, are visible upon exhalation by the user.
Although, many e-cigarettes formulations contain nicotine, their use as a means to quit smoking can be inadequate for various reasons, such as: (i) the nicotine concentration in the formulation can be too low, (ii) a considerable amount of nicotine can be lost by not being captured by the body, and (iii) given the visible aerosol they often generate, their use is not discreet and mimics the habit that the user desires to quit. Thus, there is a need to develop liquid formulation containing a high concentration of nicotine whose generated aerosol is less visible and is better retained in the oral and respiratory tracts.
Summary of the Invention In one aspect, the present invention features a method of administering nicotine or a salt thereof to a human, wherein the method includes inhaling an aerosol of a liquid formulation, the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol.
In another aspect, the present invention features an aerosol-generating device comprising a reservoir containing a liquid formulation, wherein the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof;
wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol and wherein the aerosol-generating device is arranged and configured to generate an aerosol of said liquid formulation.
io In still another aspect, the present invention features a reservoir containing a liquid formulation, wherein the liquid formulation comprising: (i) at least 12 percent by weight of water; (ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof; wherein the liquid formulation includes no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol and wherein the reservoir is arranged and configured to attach to an aerosol-generating device to provide fluid communication for such liquid formulation from the reservoir to the aerosol- generating device.
Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims.
Detailed Description of the Invention It is believed that one skilled in the art can, based upon the description herein, utilizes the present invention to its fullest extent. The following specific embodiments can be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. As used herein, all percentages are by weight unless otherwise specified.
2 Liquid Formulation As discussed above, the liquid formulation includes at least 12 percent by weight of water, at least 70 percent by weight of propylene glycol; and at least 2 percent by weight of nicotine or a salt thereof. In one embodiment, the liquid formulation contains at least 15 percent by weight of water, such as at least 20 percent by weight of water. In one embodiment, the liquid formulation contains up to 28 percent by weight of water, such as up to 25 percent by weight of water, such as up to 20 percent by weight water. In one embodiment, the liquid formulation contains at least 75 percent by weight of propylene glycol, such as at least 80 percent by weight of propylene glycol. In one embodiment, the liquid formulation contains up to 86 percent by weight of propylene glycol, such as up to 80 percent by weight of propylene glycol, such as up to 75 percent by weight propylene glycol.
In one embodiment, the liquid formulation includes from 15 to 25 percent by weight of water, from 70 to 80 percent by weight of propylene glycol; and from 2 to 10 percent by weight of nicotine or a salt thereof.
Further, the liquid formulation includes no more than 5 percent by weight by weight of glycerol, such as no more than 1 percent by weight of glycerol, such as including no glycerol. As discussed above, the presence of glycerol in the formulation will result in a more visible aerosol form of the liquid formulation. Further, glycerol has a higher boiling point than propylene glycol, which would thus potentially raise the boiling point of the liquid formulation. Still further, glycerol can crystalize at low temperatures.
Still further, the liquid formulation includes no more than 5 percent by weight of ethanol, such as no more than 1 percent by weight of ethanol, such as including no ethanol.
The inclusion of ethanol is not desired because of both the risk of separation due to rapid evaporation when heating the formulation to create an aerosol as well as the desire of certain users to avoid the intake of ethanol into their body.
As discussed above, the liquid formulation includes at least 12 percent by weight of water (e.g., from 12 to 28 percent water). As discussed below in the examples, Applicants have found that such a concentration of water lowers the boiling point of the liquid formulation while still maintaining at an acceptably low water activity to inhibit microbial activity (e.g., a water activity of less than 0.6). In one embodiment, the boiling point of the liquid formulation is less than 125 C, such as from 105 C to 125 C (e.g., when measured using the method recited in the European Pharmacopoeia 8th Edition 2.2.12).
In one embodiment, the liquid formulation includes from 15 to 25 percent by weight of water, from 70 to 80 percent by weight of propylene glycol; and from 2 to 10 percent by weight of nicotine or a salt thereof.
Further, the liquid formulation includes no more than 5 percent by weight by weight of glycerol, such as no more than 1 percent by weight of glycerol, such as including no glycerol. As discussed above, the presence of glycerol in the formulation will result in a more visible aerosol form of the liquid formulation. Further, glycerol has a higher boiling point than propylene glycol, which would thus potentially raise the boiling point of the liquid formulation. Still further, glycerol can crystalize at low temperatures.
Still further, the liquid formulation includes no more than 5 percent by weight of ethanol, such as no more than 1 percent by weight of ethanol, such as including no ethanol.
The inclusion of ethanol is not desired because of both the risk of separation due to rapid evaporation when heating the formulation to create an aerosol as well as the desire of certain users to avoid the intake of ethanol into their body.
As discussed above, the liquid formulation includes at least 12 percent by weight of water (e.g., from 12 to 28 percent water). As discussed below in the examples, Applicants have found that such a concentration of water lowers the boiling point of the liquid formulation while still maintaining at an acceptably low water activity to inhibit microbial activity (e.g., a water activity of less than 0.6). In one embodiment, the boiling point of the liquid formulation is less than 125 C, such as from 105 C to 125 C (e.g., when measured using the method recited in the European Pharmacopoeia 8th Edition 2.2.12).
3 Maintaining the boiling point above 105 C (e.g., by maintaining at least 70 percent by weight of propylene glycol) but below 125 C not only allows for the creation of the aerosol at a temperature less than the temperature needed to create an aerosol with just propylene glycol and/or glycerol, but it also may help prevent the fractionation of water and propylene glycol during such process which may help maintain a uniform nicotine concentration within the resulting aerosol.
In one embodiment, the viscosity of the liquid formulation is less than 75mPa.s, such as less than 50mPa.s, such as less than 30mPa.s (e.g., when measured using the method recited in the European Pharmacopoeia 8th Edition 2.2.8 at 20 C).
in In one embodiment, the liquid formulation is manufactured by simple mixing of all the ingredients. Liquid ingredients are generally miscible with each other, while any solid ingredients may need to be dissolved in the mixture. Gentle heating of the constituent can help to dissolve solid components more rapidly.
Nicotine The liquid formulation contains at least 2 percent by weight of nicotine or a salt thereof. In one embodiment, the liquid formulation includes nicotine (i.e., the free base of nicotine). In one embodiment, the liquid formulation includes a salt of nicotine. Examples of nicotine salts include, but are not limited to, formic (2:1), acetic (3:1), propionic (3:1), butyric (3:1), 2-methylbutyric (3:1), 3-methylbutynic (3:1), valeric (3:1), lauric (3:1), palmitic (3:1), tartaric (1:1) and (2:1), citric (2:1), malic (2:1), oxalic (2:1), benzoic (1:1), gentisic (1:1), gallic (1:1), phenylacetic (3:1), salicylic (1:1), phthalic (1:1), picric (2:1), sulfosalicylic (1:1), tannic (1:5), pectic (1:3), alginic (1:2), hydrochloric (2:1), chloroplatinic (1:1), silcotungstic (1:1), pyruvic (2:1), glutamic (1:1), and aspartic (1:1) salts of nicotine.
While the use of the free base of nicotine is generally preferred, the use of such salts may be desirable to lower the pH to potentially reduce irritation for liquid formulations containing a high concentration of nicotine.
As discussed above, the liquid formulation contains at least 2 percent by weight of nicotine or a salt thereof, such as from 2 to 10 percent, such as from 3 to 8 percent, such as from 3 to 6 percent by weight of nicotine or a salt thereof. In one embodiment, the liquid formulation contains at least 3 percent by weight (e.g., 3-8 percent by weight), such as at least 4 percent by weight (e.g., 4-8 percent by weight), such as at least 5 percent by weight (e.g., 5-8 percent by weight) of nicotine or a salt thereof. Benefits of such a high
In one embodiment, the viscosity of the liquid formulation is less than 75mPa.s, such as less than 50mPa.s, such as less than 30mPa.s (e.g., when measured using the method recited in the European Pharmacopoeia 8th Edition 2.2.8 at 20 C).
in In one embodiment, the liquid formulation is manufactured by simple mixing of all the ingredients. Liquid ingredients are generally miscible with each other, while any solid ingredients may need to be dissolved in the mixture. Gentle heating of the constituent can help to dissolve solid components more rapidly.
Nicotine The liquid formulation contains at least 2 percent by weight of nicotine or a salt thereof. In one embodiment, the liquid formulation includes nicotine (i.e., the free base of nicotine). In one embodiment, the liquid formulation includes a salt of nicotine. Examples of nicotine salts include, but are not limited to, formic (2:1), acetic (3:1), propionic (3:1), butyric (3:1), 2-methylbutyric (3:1), 3-methylbutynic (3:1), valeric (3:1), lauric (3:1), palmitic (3:1), tartaric (1:1) and (2:1), citric (2:1), malic (2:1), oxalic (2:1), benzoic (1:1), gentisic (1:1), gallic (1:1), phenylacetic (3:1), salicylic (1:1), phthalic (1:1), picric (2:1), sulfosalicylic (1:1), tannic (1:5), pectic (1:3), alginic (1:2), hydrochloric (2:1), chloroplatinic (1:1), silcotungstic (1:1), pyruvic (2:1), glutamic (1:1), and aspartic (1:1) salts of nicotine.
While the use of the free base of nicotine is generally preferred, the use of such salts may be desirable to lower the pH to potentially reduce irritation for liquid formulations containing a high concentration of nicotine.
As discussed above, the liquid formulation contains at least 2 percent by weight of nicotine or a salt thereof, such as from 2 to 10 percent, such as from 3 to 8 percent, such as from 3 to 6 percent by weight of nicotine or a salt thereof. In one embodiment, the liquid formulation contains at least 3 percent by weight (e.g., 3-8 percent by weight), such as at least 4 percent by weight (e.g., 4-8 percent by weight), such as at least 5 percent by weight (e.g., 5-8 percent by weight) of nicotine or a salt thereof. Benefits of such a high
4 concentration of nicotine include reducing the amount of vapor needed to deliver a specified amount of nicotine and reducing the number of inhalations needed to release the dose.
Aerosol-generating Device Numerous commercially available aerosol-generating devices have been developed to administer a liquid formulation as an aerosol to a user. In one embodiment, the aerosol-generating device is disposable after the liquid formulation stored within a reservoir within the device is exhausted. See, e.g., Njoy0 King electronic cigarettes (Njoy, Scottsdale, Arizona) and VypeTM (CN Creative, Manchester, England). In one embodiment, the aerosol-generating device comprises a reservoir for the liquid formulation that is replaceable once the liquid formulation is exhausted. See, e.g., VuseTM digital vapor cigarettes (RJ Reynolds Vapor Company, Winston-Salem, NC) and VypeTM Reload (CN Creative, Manchester, England) and US Patent No. 2013/0192617. In one embodiment, the aerosol-generating device thermally creates the aerosol. See, e.g., US Patent Nos. 2014/0000638 and 2013/0192617 and European Patent No. 1618803. In one embodiment, the aerosol-generating device creates the aerosol through mechanical formation, such as a nebulizer (e.g., ultrasonic and pneumatic nebulizers such has disclosed in US Patent No. 8,127,772).
Optical Density of Aerosol The optical density of the aerosol may be determined using the method of Example 5 of this application ("Optical Density"). In one embodiment, the Optical Density of the aerosol is less than 0.05, such as less than 0.025, such as less than 0.01, such as less than 0.005, such as less than 0.001 where such Optical Density is measured at 5, 10, 15, and/or 20 seconds. In one embodiment, the Optical Density of the aerosol is less than 0.01 at 10 seconds, such as less than 0.005 at 5 seconds, such as less than 0.005 at 10 seconds, such as less than 0.005 at 5 seconds.
Use of Aerosol of Liquid Formulation In one embodiment, the method, reservoir, and/or device of the present invention is used as an aid to smoking cessation, including but not limited to reliving and/or preventing withdrawal symptoms and/or reducing smoking cravings (e.g., for a user that is trying to stop smoking or reduce the number of cigarettes smoked). In one embodiment, the method includes the administration of from about 0.01mg to about 0.25 mg of nicotine per inhalation
Aerosol-generating Device Numerous commercially available aerosol-generating devices have been developed to administer a liquid formulation as an aerosol to a user. In one embodiment, the aerosol-generating device is disposable after the liquid formulation stored within a reservoir within the device is exhausted. See, e.g., Njoy0 King electronic cigarettes (Njoy, Scottsdale, Arizona) and VypeTM (CN Creative, Manchester, England). In one embodiment, the aerosol-generating device comprises a reservoir for the liquid formulation that is replaceable once the liquid formulation is exhausted. See, e.g., VuseTM digital vapor cigarettes (RJ Reynolds Vapor Company, Winston-Salem, NC) and VypeTM Reload (CN Creative, Manchester, England) and US Patent No. 2013/0192617. In one embodiment, the aerosol-generating device thermally creates the aerosol. See, e.g., US Patent Nos. 2014/0000638 and 2013/0192617 and European Patent No. 1618803. In one embodiment, the aerosol-generating device creates the aerosol through mechanical formation, such as a nebulizer (e.g., ultrasonic and pneumatic nebulizers such has disclosed in US Patent No. 8,127,772).
Optical Density of Aerosol The optical density of the aerosol may be determined using the method of Example 5 of this application ("Optical Density"). In one embodiment, the Optical Density of the aerosol is less than 0.05, such as less than 0.025, such as less than 0.01, such as less than 0.005, such as less than 0.001 where such Optical Density is measured at 5, 10, 15, and/or 20 seconds. In one embodiment, the Optical Density of the aerosol is less than 0.01 at 10 seconds, such as less than 0.005 at 5 seconds, such as less than 0.005 at 10 seconds, such as less than 0.005 at 5 seconds.
Use of Aerosol of Liquid Formulation In one embodiment, the method, reservoir, and/or device of the present invention is used as an aid to smoking cessation, including but not limited to reliving and/or preventing withdrawal symptoms and/or reducing smoking cravings (e.g., for a user that is trying to stop smoking or reduce the number of cigarettes smoked). In one embodiment, the method includes the administration of from about 0.01mg to about 0.25 mg of nicotine per inhalation
5 (e.g., the device utilizing the liquid formulation is arranged and configured to generate an aerosol of the liquid formulation containing from about 0.05 mg to about 0.15 mg of nicotine per inhalation.
Examples Specific embodiments of the present invention are illustrated by way of the following examples. This invention is not confined to the specific limitations set forth in these examples.
Example 1: Measurement of Boiling Point Various liquid formulations including nicotine, water, and/or propylene glycol are set-forth below in Table 1. These examples were manufactured as follows. First, all the ingredients were weighed. The Nicotine free base was added to the water, and then propylene glycol was added to nicotine/water solution followed by simple mixing to obtain homogenous liquid formulation. The boiling points for each of the formulations were measured and are recorded in Table 1.
Table 1 Propylene Glycol Water Nicotine Boiling Point (w/w %) (w/w %) (w/w %) ( C)*
Example lA 100 0 0 188 Example 1B 97 0 3 147.2 Example 1C 89.1 9.9 1 122.4 Example 1D 90 10 0 121.7 Example lE 77.6 19.6 2 116.0 Example 1F 58.8 39.2 2 108.5 Example 1G 39.2 58.8 2 105.6 Example 1H 19.6 77.6 2 102.0 Example 11 0 98 2 99.2 * Boiling point was measured using the method described in the European Pharmacopoeia 8th Edition 2.2.8 Thus, as indicated in Table 1, even the mere addition of 10% water reduced the boiling point of the liquid formulation from 188 to 121.7 C. Such a reduction allows the liquid formulation to form an aerosol at a much lower temperature.
Examples Specific embodiments of the present invention are illustrated by way of the following examples. This invention is not confined to the specific limitations set forth in these examples.
Example 1: Measurement of Boiling Point Various liquid formulations including nicotine, water, and/or propylene glycol are set-forth below in Table 1. These examples were manufactured as follows. First, all the ingredients were weighed. The Nicotine free base was added to the water, and then propylene glycol was added to nicotine/water solution followed by simple mixing to obtain homogenous liquid formulation. The boiling points for each of the formulations were measured and are recorded in Table 1.
Table 1 Propylene Glycol Water Nicotine Boiling Point (w/w %) (w/w %) (w/w %) ( C)*
Example lA 100 0 0 188 Example 1B 97 0 3 147.2 Example 1C 89.1 9.9 1 122.4 Example 1D 90 10 0 121.7 Example lE 77.6 19.6 2 116.0 Example 1F 58.8 39.2 2 108.5 Example 1G 39.2 58.8 2 105.6 Example 1H 19.6 77.6 2 102.0 Example 11 0 98 2 99.2 * Boiling point was measured using the method described in the European Pharmacopoeia 8th Edition 2.2.8 Thus, as indicated in Table 1, even the mere addition of 10% water reduced the boiling point of the liquid formulation from 188 to 121.7 C. Such a reduction allows the liquid formulation to form an aerosol at a much lower temperature.
6
7 Example 2: Water Activity Water activity, or aw, is the partial vapor pressure of water in a substance divided by the standard state partial vapor pressure of water. Water activity is based on a scale of 0 to 1.0 with pure water having a water activity of 1Ø Usually products that contain lower percent moisture have lower water activity. Water activity is an important characteristic to determine the antimicrobial properties of the formulation. Since yeast, molds, and bacteria require a certain amount of available water to support growth, designing a formulation with a water activity below 0.6 provides an effective control against such growth.
io Various liquid formulations including nicotine, water, and/or propylene glycol are set-forth below in Table 2. These examples were manufactured as set forth in Example 1. The water activity (aw) of these formulations was measured using an AquaLab 4TEV
(Pullman, WA USA) chilled mirror water activity instrument and recorded in Table 2.
Table 2 Propylene Glycol Water Nicotine Water (w/w %) (w/w %) (w/w %) Activity*
Example 2A 100 0 0 0.18 Example 2B 89.1 9.9 1 0.44 Example 2C 87.3 9.7 3 0.43 Example 2D 78.4 19.6 2 0.57 Example 2E 68.6 29.4 2 0.69 Example 2F 58.8 39.2 2 0.77 Example 2G 88.2 9.8 2 0.35 Example 2H 78.4 19.6 2 0.54 Example 21 68.6 29.4 2 0.66 Example 2J 58.8 39.2 2 0.74 Example 2K 86.4 9.6 4 0.35 Example 2L 76.8 19.2 4 0.54 Example 2M 67.2 28.8 4 0.67 Example 2N 57.6 38.4 4 0.75 * The water activity was measured by an AquaLab 4TEV apparatus.
Formulations containing less than 20% w/w of water were able to maintain a water activity of less than 0.6. Further, as seen when comparing below Examples 2B and 2C, changing the concentration of nicotine from 1 to 3 percent did not have a significant effect on the water activity of the liquid formulation.
Example 3: Aerosol Visibility Various liquid formulations including nicotine, water, and/or propylene glycol are set-forth below in Table 3. These examples were manufactured as set forth in Example 1.
Table 3 Composition w/w% Test results Propylene Water Boiling Point Viscosity Formulations Nicotine Water glycol Activity* ( C)**
mPa.s***
Example 3A 3.00 0.00 97.00 0.00 147.2 56,601 Example 3B 4.50 0.00 95.50 0.00 151.7 61,101 Example 3C 3.00 4.85 92.15 0.22 134.2 51,218 Example 3D 4.50 4.78 90.73 0.21 125.6 47,637 Example 3E 3.00 9.70 87.30 0.35 121.2 30,481 Example 3F 4.50 9.55 85.95 0.35 126.4 41,132 Example 3G 3.00 19.40 77.60 0.55 114.7 25,756 Example 3H 4.50 19.10 76.40 0.55 111.8 22,392 Example 31 3.00 29.10 67.90 0.68 110.2 16,827 Example 3J 4.50 28.65 66.85 0.68 108.5 14,301 Example 3K 3.00 38.80 58.20 0.75 106.6 11,223 Example 3L 4.50 38.20 57.30 0.76 105.1 10,827 Example 3M 6 28.20 65.80 0.65 104.0 14,662 Example 3N 6 18.80 75.20 0.53 106.6 21,160 Example 30 6 9.40 84.60 0.34 113.1 30,847 * The water activity was measured by an AquaLab 4TEV apparatus.
** Boiling point was measured using the method described in the European Pharmacopoeia 8th Edition 2.2.8 *** Viscosity was measured using the method described in the European Pharmacopoeia 8th Edition 2.2.8 at 20 C
io Various liquid formulations including nicotine, water, and/or propylene glycol are set-forth below in Table 2. These examples were manufactured as set forth in Example 1. The water activity (aw) of these formulations was measured using an AquaLab 4TEV
(Pullman, WA USA) chilled mirror water activity instrument and recorded in Table 2.
Table 2 Propylene Glycol Water Nicotine Water (w/w %) (w/w %) (w/w %) Activity*
Example 2A 100 0 0 0.18 Example 2B 89.1 9.9 1 0.44 Example 2C 87.3 9.7 3 0.43 Example 2D 78.4 19.6 2 0.57 Example 2E 68.6 29.4 2 0.69 Example 2F 58.8 39.2 2 0.77 Example 2G 88.2 9.8 2 0.35 Example 2H 78.4 19.6 2 0.54 Example 21 68.6 29.4 2 0.66 Example 2J 58.8 39.2 2 0.74 Example 2K 86.4 9.6 4 0.35 Example 2L 76.8 19.2 4 0.54 Example 2M 67.2 28.8 4 0.67 Example 2N 57.6 38.4 4 0.75 * The water activity was measured by an AquaLab 4TEV apparatus.
Formulations containing less than 20% w/w of water were able to maintain a water activity of less than 0.6. Further, as seen when comparing below Examples 2B and 2C, changing the concentration of nicotine from 1 to 3 percent did not have a significant effect on the water activity of the liquid formulation.
Example 3: Aerosol Visibility Various liquid formulations including nicotine, water, and/or propylene glycol are set-forth below in Table 3. These examples were manufactured as set forth in Example 1.
Table 3 Composition w/w% Test results Propylene Water Boiling Point Viscosity Formulations Nicotine Water glycol Activity* ( C)**
mPa.s***
Example 3A 3.00 0.00 97.00 0.00 147.2 56,601 Example 3B 4.50 0.00 95.50 0.00 151.7 61,101 Example 3C 3.00 4.85 92.15 0.22 134.2 51,218 Example 3D 4.50 4.78 90.73 0.21 125.6 47,637 Example 3E 3.00 9.70 87.30 0.35 121.2 30,481 Example 3F 4.50 9.55 85.95 0.35 126.4 41,132 Example 3G 3.00 19.40 77.60 0.55 114.7 25,756 Example 3H 4.50 19.10 76.40 0.55 111.8 22,392 Example 31 3.00 29.10 67.90 0.68 110.2 16,827 Example 3J 4.50 28.65 66.85 0.68 108.5 14,301 Example 3K 3.00 38.80 58.20 0.75 106.6 11,223 Example 3L 4.50 38.20 57.30 0.76 105.1 10,827 Example 3M 6 28.20 65.80 0.65 104.0 14,662 Example 3N 6 18.80 75.20 0.53 106.6 21,160 Example 30 6 9.40 84.60 0.34 113.1 30,847 * The water activity was measured by an AquaLab 4TEV apparatus.
** Boiling point was measured using the method described in the European Pharmacopoeia 8th Edition 2.2.8 *** Viscosity was measured using the method described in the European Pharmacopoeia 8th Edition 2.2.8 at 20 C
8 These liquid formulations were tested with an aerosol-generating device composed of a cartomizer (Boge 510 Standard Resistance, Vaper Venue, Buena Park, CA) fitted to a battery (510 Titan Tank 340mAh Mega Automatic Battery, Totally Wicked Blackburn Lancashire, United Kingdom). About 0.8g of a formulation was filled into the liquid reservoir of the cartomizer, which was then fitted to the battery. The liquid formulations were tested for nicotine release using an in vitro puffing method. The aerosol generated by the device was captured and the nicotine level was determined. The result showed uniformity in nicotine release. For certain formulations in Table 3 more than 90% of the nicotine concentration of in the formulation was measured in the captured aerosol.
All aerosols according to above Table 3 were less visible than the aerosols from a large number of commercial e-cigarettes. The aerosols according to Table 3 disappeared more rapidly upon dilution with the air. A slight additional decrease in aerosol visibility and duration was also noticed with increasing proportion of water in the formulations.
Example 4: Formulation Stability The stability of Example 3N was followed during 12 weeks at three storage conditions: 25 C/60% RH (Table 4A), 40 C/75% RH (Table 4B), and 60 C ambient %
RH
(Table 4C). A gradient ultra-high performance liquid chromatography (UHPLC) method using a C18 column withstanding high pH and acetonitrile/ammonium acetate buffer as the eluent with UV detection at 230 to 260 nm. The results show an acceptable stability under these storage conditions.
All aerosols according to above Table 3 were less visible than the aerosols from a large number of commercial e-cigarettes. The aerosols according to Table 3 disappeared more rapidly upon dilution with the air. A slight additional decrease in aerosol visibility and duration was also noticed with increasing proportion of water in the formulations.
Example 4: Formulation Stability The stability of Example 3N was followed during 12 weeks at three storage conditions: 25 C/60% RH (Table 4A), 40 C/75% RH (Table 4B), and 60 C ambient %
RH
(Table 4C). A gradient ultra-high performance liquid chromatography (UHPLC) method using a C18 column withstanding high pH and acetonitrile/ammonium acetate buffer as the eluent with UV detection at 230 to 260 nm. The results show an acceptable stability under these storage conditions.
9 Table 4A
Storage time (weeks) Attributes Method Specification Units Limits 0 4 8 Visual Clear Clear Clear Clear Description' inspection Informative solution solution solution solution Rt Rt Rt Rt Nicotine Rt matches matches matches matches matches identity2 UHPLC standard standard standard standard standard mg/m Nicotine Assay5 UHPLC 54.0-66.0 1 61.7 61.4 62.7 62.5 Impurities3' 5 Cotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nicotine-cis-N-oxide UHPLC Informative % 1.c. n.d n.d n.d n.d Nicotine-trans-N-oxide UHPLC Informative % 1.c. n.d n.d n.d n.d Norcotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nornicotine UHPLC Informative % 1.c. 0.11 0.13 0.11 0.10 13-Nicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d 13-Nornicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d Myosmine UHPLC Informative % 1.c. n.d 0,05 0,07 0,07 MNP4 UHPLC Informative % 1.c. n.d n.d 0,03 0,04 Any unspecified UHPLC Informative % 1.c. n.d n.d n.d n.d Sum UHPLC Informative % 1.c. 0.11 0.18 0.21 0.21 'Clear, colorless solution 2 Conforms to test- retention time matches standard.
3 No peaks smaller than the integration threshold (IT) are integrated, IT is defined as the area, which is 0.05 % of the nicotine peak area (the average peak area of the system suitability solution for nicotine). Peaks below IT are reported as n.d.
4 1-methy1-3-nicotinoylpyrrolidine 5 "% 1.c." is the percent related substance of nicotine label claim, "n.a."
and "n.d." stands for not analyzed and not detected, respectively Table 4B
Storage time (weeks) Attributes Method Specification Units Limits 0 4 8 Visual Clear Clear Clear Clear Description' inspection Informative solution solution solution solution Rt Rt Rt Rt Nicotine Rt matches matches matches matches matches identity2 UHPLC standard standard standard standard standard Nicotine Assay5 UHPLC 54.0-66.0 mg/ml 61.7 62.0 62.5 61.8 Impurities3' 5 Cotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nicotine-cis-N-oxide UHPLC Informative % 1.c. n.d n.d 0.06 0.13 Nicotine-trans-N-oxide UHPLC Informative % 1.c. n.d 0.09 0.14 0.25 Norcotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nornicotine UHPLC Informative % 1.c. 0.11 0.13 0.10 0.12 13-Nicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d 13-Nornicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d Myosmine UHPLC Informative % 1.c. n.d 0.05 0.05 0.07 MNP4 UHPLC Informative % 1.c. n.d 0.04 0.04 0.04 Any unspecified UHPLC Informative % 1.c. n.d n.d n.d n.d Sum UHPLC Informative % 1.c. 0.11 0.31 0.39 0.61 'Clear, colorless solution 2 Conforms to test- retention time matches standard.
3 No peaks smaller than the integration threshold (IT) are integrated, IT is defined as the area, which is 0.05 % of the nicotine peak area (the average peak area of the system suitability solution for nicotine). Peaks below IT are reported as n.d.
4 1-methy1-3-nicotinoylpyrrolidine 5 "% 1.c." is the percent related substance of nicotine label claim, "n.a."
and "n.d." stands for not analyzed and not detected, respectively Table 4C
Storage time (weeks) Attributes Method Specification Units limits 0 4 8 Visual Clear Clear Clear Clear Description' inspection Informative solution solution solution solution Rt Rt Rt Rt Nicotine Rt matches matches matches matches matches identity2 UHPLC standard standard standard standard standard Nicotine Assay5 UHPLC 54.0-66.0 mg/ml 61.7 61.4 62.7 62.5 Impurities3' 5 Cotinine UHPLC Informative % 1.c. n.d n.d 0.04 0.07 Nicotine-cis-N-oxide UHPLC Informative % 1.c. n.d 0.21 0.46 0.74 Nicotine-trans-N-oxide UHPLC Informative % 1.c. n.d 0.43 0.87 1.27 Norcotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nornicotine UHPLC Informative % 1.c. 0.11 0.12 0.11 0.14 13-Nicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d 13-Nornicotyrine UHPLC Informative % 1.c. n.d n.d n.d 0.02 Myosmine UHPLC Informative % 1.c. n.d 0.07 0.08 0.09 MNP4 UHPLC Informative % 1.c. n.d 0.07 0.07 0.10 Any unspecified UHPLC Informative % 1.c. n.d n.d n.d 0.11 Sum UHPLC Informative % 1.c. 0.11 0.90 1.63 2.54 'Clear, colorless solution 2 Conforms to test- retention time matches standard.
3 No peaks smaller than the integration threshold (IT) are integrated, IT is defined as the area, which is 0.05 % of the nicotine peak area (the average peak area of the system suitability solution for nicotine). Peaks below IT are reported as n.d.
4 1-methy1-3-nicotinoylpyrrolidine 5 "% 1.c." is the percent related substance of nicotine label claim, "n.a."
and "n.d." stands for not analyzed and not detected, respectively Example 5: Optical Density of Aerosol The optical densities of aerosols produced from two formulations of the present invention were compared to aerosols produced by five commercially-available, nicotine aerosol-generating devices. The optical density of the aerosol produced by these seven formulations was tested in an in vitro model. For this model, a four liter cylindrical chamber was constructed having a radius of 12.5cm and the top and bottom constructed of clear polycarbonate to allow for the measurement of the optical density of the aerosol introduced into the chamber using a photometer (Hagner Photometer, Hagner Photometric Instruments Ltd., Havant, Sweden) positioned on one side of the chamber and a white light source positioned on the other side of the chamber. The chamber contains an aerosol introduction tube that forces air at a rate of 1 L/min for 3 seconds through the air inlet hole of the respective aerosol-generating devices and directs the resulting aerosol (50m1 of aerosol) into the chamber. The chamber further contains both a fan (a 50mm fan running at approximately 2 CFM) to promote mixing and homogenization of introduced aerosol and a io one way air check valve to both release any pressure increase within the chamber following introduction of the aerosol and allow flushing of the chamber in between each test.
For each device, the optical density was calculated using the following equation:
Optical Density = - logio (I/I0) where I = light intensity and Io = initial light intensity Measurements were taken for 20 seconds following first instruction of the aerosol into the chamber (i.e., for the 3 seconds that the aerosol was introduced and for the seventeen seconds afterwards). The results of the studies are set forth below in Table 5.
Table 5 Optical Density Formulation 5 sec 10 sec 15 sec 20 sec Example 3F1 0.002 0.000 0.002 0.002 Example 3J1 0.000 0.000 0.000 0.000 VypeTM Classic Regular2 0.087 0.087 0.092 0.092 VypeTM Classic Bold2 0.083 0.086 0.086 0.086 NjoyTm King Gold3 0.066 0.063 0.063 0.063 NjoyTm King Bold3 0.104 0.101 0.101 0.101 VuseTM Original4 0.079 0.076 0.076 0.076 1 Aerosols of Examples 3F and 3J were created with a Joyetech 510-T body (Joyetech USA
Inc, Irvine, CA) with Boge 510 cartomizer 2 Nicoventures Ltd., London, UK
3 Njoy, Scottsdale, AZ
4 RJ Reynolds Vapor, Salem, NC
As is evident from the result in Table 5, Examples 3F and 3J produced unexpected, minimally persistent aerosols compared to tested commercial formulations. The Optical Density of Example 3F ranged between 0 and 0.002 while the Optical Density of Example 3J
was 0 from 5-20 seconds. The five commercially available devices produced aerosols having much higher Optical Densities, ranging from 0.063 to 0.104 from 5-20 seconds.
It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.
What is claimed is:
Storage time (weeks) Attributes Method Specification Units Limits 0 4 8 Visual Clear Clear Clear Clear Description' inspection Informative solution solution solution solution Rt Rt Rt Rt Nicotine Rt matches matches matches matches matches identity2 UHPLC standard standard standard standard standard mg/m Nicotine Assay5 UHPLC 54.0-66.0 1 61.7 61.4 62.7 62.5 Impurities3' 5 Cotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nicotine-cis-N-oxide UHPLC Informative % 1.c. n.d n.d n.d n.d Nicotine-trans-N-oxide UHPLC Informative % 1.c. n.d n.d n.d n.d Norcotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nornicotine UHPLC Informative % 1.c. 0.11 0.13 0.11 0.10 13-Nicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d 13-Nornicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d Myosmine UHPLC Informative % 1.c. n.d 0,05 0,07 0,07 MNP4 UHPLC Informative % 1.c. n.d n.d 0,03 0,04 Any unspecified UHPLC Informative % 1.c. n.d n.d n.d n.d Sum UHPLC Informative % 1.c. 0.11 0.18 0.21 0.21 'Clear, colorless solution 2 Conforms to test- retention time matches standard.
3 No peaks smaller than the integration threshold (IT) are integrated, IT is defined as the area, which is 0.05 % of the nicotine peak area (the average peak area of the system suitability solution for nicotine). Peaks below IT are reported as n.d.
4 1-methy1-3-nicotinoylpyrrolidine 5 "% 1.c." is the percent related substance of nicotine label claim, "n.a."
and "n.d." stands for not analyzed and not detected, respectively Table 4B
Storage time (weeks) Attributes Method Specification Units Limits 0 4 8 Visual Clear Clear Clear Clear Description' inspection Informative solution solution solution solution Rt Rt Rt Rt Nicotine Rt matches matches matches matches matches identity2 UHPLC standard standard standard standard standard Nicotine Assay5 UHPLC 54.0-66.0 mg/ml 61.7 62.0 62.5 61.8 Impurities3' 5 Cotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nicotine-cis-N-oxide UHPLC Informative % 1.c. n.d n.d 0.06 0.13 Nicotine-trans-N-oxide UHPLC Informative % 1.c. n.d 0.09 0.14 0.25 Norcotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nornicotine UHPLC Informative % 1.c. 0.11 0.13 0.10 0.12 13-Nicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d 13-Nornicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d Myosmine UHPLC Informative % 1.c. n.d 0.05 0.05 0.07 MNP4 UHPLC Informative % 1.c. n.d 0.04 0.04 0.04 Any unspecified UHPLC Informative % 1.c. n.d n.d n.d n.d Sum UHPLC Informative % 1.c. 0.11 0.31 0.39 0.61 'Clear, colorless solution 2 Conforms to test- retention time matches standard.
3 No peaks smaller than the integration threshold (IT) are integrated, IT is defined as the area, which is 0.05 % of the nicotine peak area (the average peak area of the system suitability solution for nicotine). Peaks below IT are reported as n.d.
4 1-methy1-3-nicotinoylpyrrolidine 5 "% 1.c." is the percent related substance of nicotine label claim, "n.a."
and "n.d." stands for not analyzed and not detected, respectively Table 4C
Storage time (weeks) Attributes Method Specification Units limits 0 4 8 Visual Clear Clear Clear Clear Description' inspection Informative solution solution solution solution Rt Rt Rt Rt Nicotine Rt matches matches matches matches matches identity2 UHPLC standard standard standard standard standard Nicotine Assay5 UHPLC 54.0-66.0 mg/ml 61.7 61.4 62.7 62.5 Impurities3' 5 Cotinine UHPLC Informative % 1.c. n.d n.d 0.04 0.07 Nicotine-cis-N-oxide UHPLC Informative % 1.c. n.d 0.21 0.46 0.74 Nicotine-trans-N-oxide UHPLC Informative % 1.c. n.d 0.43 0.87 1.27 Norcotinine UHPLC Informative % 1.c. n.d n.d n.d n.d Nornicotine UHPLC Informative % 1.c. 0.11 0.12 0.11 0.14 13-Nicotyrine UHPLC Informative % 1.c. n.d n.d n.d n.d 13-Nornicotyrine UHPLC Informative % 1.c. n.d n.d n.d 0.02 Myosmine UHPLC Informative % 1.c. n.d 0.07 0.08 0.09 MNP4 UHPLC Informative % 1.c. n.d 0.07 0.07 0.10 Any unspecified UHPLC Informative % 1.c. n.d n.d n.d 0.11 Sum UHPLC Informative % 1.c. 0.11 0.90 1.63 2.54 'Clear, colorless solution 2 Conforms to test- retention time matches standard.
3 No peaks smaller than the integration threshold (IT) are integrated, IT is defined as the area, which is 0.05 % of the nicotine peak area (the average peak area of the system suitability solution for nicotine). Peaks below IT are reported as n.d.
4 1-methy1-3-nicotinoylpyrrolidine 5 "% 1.c." is the percent related substance of nicotine label claim, "n.a."
and "n.d." stands for not analyzed and not detected, respectively Example 5: Optical Density of Aerosol The optical densities of aerosols produced from two formulations of the present invention were compared to aerosols produced by five commercially-available, nicotine aerosol-generating devices. The optical density of the aerosol produced by these seven formulations was tested in an in vitro model. For this model, a four liter cylindrical chamber was constructed having a radius of 12.5cm and the top and bottom constructed of clear polycarbonate to allow for the measurement of the optical density of the aerosol introduced into the chamber using a photometer (Hagner Photometer, Hagner Photometric Instruments Ltd., Havant, Sweden) positioned on one side of the chamber and a white light source positioned on the other side of the chamber. The chamber contains an aerosol introduction tube that forces air at a rate of 1 L/min for 3 seconds through the air inlet hole of the respective aerosol-generating devices and directs the resulting aerosol (50m1 of aerosol) into the chamber. The chamber further contains both a fan (a 50mm fan running at approximately 2 CFM) to promote mixing and homogenization of introduced aerosol and a io one way air check valve to both release any pressure increase within the chamber following introduction of the aerosol and allow flushing of the chamber in between each test.
For each device, the optical density was calculated using the following equation:
Optical Density = - logio (I/I0) where I = light intensity and Io = initial light intensity Measurements were taken for 20 seconds following first instruction of the aerosol into the chamber (i.e., for the 3 seconds that the aerosol was introduced and for the seventeen seconds afterwards). The results of the studies are set forth below in Table 5.
Table 5 Optical Density Formulation 5 sec 10 sec 15 sec 20 sec Example 3F1 0.002 0.000 0.002 0.002 Example 3J1 0.000 0.000 0.000 0.000 VypeTM Classic Regular2 0.087 0.087 0.092 0.092 VypeTM Classic Bold2 0.083 0.086 0.086 0.086 NjoyTm King Gold3 0.066 0.063 0.063 0.063 NjoyTm King Bold3 0.104 0.101 0.101 0.101 VuseTM Original4 0.079 0.076 0.076 0.076 1 Aerosols of Examples 3F and 3J were created with a Joyetech 510-T body (Joyetech USA
Inc, Irvine, CA) with Boge 510 cartomizer 2 Nicoventures Ltd., London, UK
3 Njoy, Scottsdale, AZ
4 RJ Reynolds Vapor, Salem, NC
As is evident from the result in Table 5, Examples 3F and 3J produced unexpected, minimally persistent aerosols compared to tested commercial formulations. The Optical Density of Example 3F ranged between 0 and 0.002 while the Optical Density of Example 3J
was 0 from 5-20 seconds. The five commercially available devices produced aerosols having much higher Optical Densities, ranging from 0.063 to 0.104 from 5-20 seconds.
It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.
What is claimed is:
Claims (20)
1. A method of administering nicotine or a salt thereof to a human, wherein said method comprises inhaling an aerosol of a liquid formulation, said liquid formulation comprising:
(i) at least 12 percent by weight of water;
(ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof;
wherein said liquid formulation comprises no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol.
(i) at least 12 percent by weight of water;
(ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of said nicotine or a salt thereof;
wherein said liquid formulation comprises no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol.
2. A method of claim 1, wherein said liquid formulation does not comprise glycerol.
3. A method of claim 1, wherein said liquid formulation does not comprise ethanol.
4. A method of claim 1, wherein said liquid formulation comprises at least 15 percent by weight of water.
5. A method of claim 1, wherein said liquid formulation comprises at least 75 percent by weight of propylene glycol.
6. A method of claim 1, wherein said liquid formulation comprises nicotine.
7. A method of claim 6, wherein said liquid formulation comprises at least 4 percent by weight of said nicotine.
8. A method of claim 1, wherein the boiling point of said liquid formulation is less than 125°C.
9. A method of claim 1, wherein the viscosity of the liquid formulation is less than 50 mPa.s.
10. A method of claim 1, wherein said aerosol has an Optical Density of less than 0.01 at 10 seconds.
11. An aerosol-generating device comprising a reservoir containing a liquid formulation, wherein said liquid formulation comprises:
(i) at least 12 percent by weight of water;
(ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of nicotine or a salt thereof;
wherein said liquid formulation comprises no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol, and wherein said aerosol-generating device is arranged and configured to generate an aerosol of said liquid formulation.
(i) at least 12 percent by weight of water;
(ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of nicotine or a salt thereof;
wherein said liquid formulation comprises no more than 5 percent by weight of glycerol and no more than 5 percent by weight of ethanol, and wherein said aerosol-generating device is arranged and configured to generate an aerosol of said liquid formulation.
12. An aerosol-generating device of claim 11, wherein said liquid formulation does not comprise glycerol.
13. An aerosol-generating device of claim 11, wherein said liquid formulation does not comprise ethanol.
14. An aerosol-generating device of claim 11, wherein said liquid formulation comprises at least 15 percent by weight of water.
15. An aerosol-generating device of claim 11, wherein said liquid formulation comprises nicotine.
16. A reservoir containing a liquid formulation, wherein said liquid formulation comprises:
(i) at least 12 percent by weight of water;
(ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of nicotine or a salt thereof;
wherein said liquid formulation comprises less than 5 percent by weight of glycerol and less than 5 percent by weight of ethanol; and wherein said reservoir is arranged and configured to attach to an aerosol-generating device to provide fluid communication for such liquid formulation from said reservoir to said aerosol generating device.
(i) at least 12 percent by weight of water;
(ii) at least 70 percent by weight of propylene glycol; and (iii) at least 2 percent by weight of nicotine or a salt thereof;
wherein said liquid formulation comprises less than 5 percent by weight of glycerol and less than 5 percent by weight of ethanol; and wherein said reservoir is arranged and configured to attach to an aerosol-generating device to provide fluid communication for such liquid formulation from said reservoir to said aerosol generating device.
17. A reservoir of claim 16, wherein said liquid formulation does not comprise glycerol.
18. A reservoir of claim 16, wherein said liquid formulation does not comprise ethanol.
19. A reservoir of claim 16, wherein said liquid formulation comprises at least 15 percent by weight of water.
20. A reservoir of claim 16, wherein said liquid formulation comprises nicotine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1450609 | 2014-05-21 | ||
SE1450609-1 | 2014-05-21 | ||
PCT/EP2015/061036 WO2015177177A1 (en) | 2014-05-21 | 2015-05-20 | A liquid formulation comprising nicotine for aerosol administration |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2949579A1 true CA2949579A1 (en) | 2015-11-26 |
Family
ID=53180743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2949579A Abandoned CA2949579A1 (en) | 2014-05-21 | 2015-05-20 | A liquid formulation comprising nicotine for aerosol administration |
Country Status (18)
Country | Link |
---|---|
US (2) | US20170079319A1 (en) |
EP (2) | EP3639813B1 (en) |
JP (1) | JP6529990B2 (en) |
KR (1) | KR102456728B1 (en) |
CN (1) | CN106413697B (en) |
AU (2) | AU2015261970A1 (en) |
CA (1) | CA2949579A1 (en) |
DK (1) | DK3639813T3 (en) |
ES (1) | ES2906209T3 (en) |
HR (1) | HRP20220075T1 (en) |
HU (1) | HUE057489T2 (en) |
IL (1) | IL248867B (en) |
LT (1) | LT3639813T (en) |
MX (1) | MX2016015179A (en) |
PL (1) | PL3639813T3 (en) |
PT (1) | PT3639813T (en) |
RU (1) | RU2707079C2 (en) |
WO (1) | WO2015177177A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12016366B2 (en) | 2019-06-07 | 2024-06-25 | Philip Morris Products S.A. | Nicotine pouch composition and pouch comprising such |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
AU2014369867A1 (en) | 2013-12-23 | 2016-06-16 | Juul Labs, Inc. | Vaporization device systems and methods |
US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
EP3821735A1 (en) | 2014-12-05 | 2021-05-19 | Juul Labs, Inc. | Calibrated dose control |
US20170079322A1 (en) * | 2015-09-18 | 2017-03-23 | Altria Client Services Llc | Liquid formulation of an electronic vapor device |
US11445574B2 (en) * | 2015-10-05 | 2022-09-13 | Lunatech, Llc | Natural-based liquid composition and electronic vaporizing devices for using such composition |
MX2018009702A (en) | 2016-02-11 | 2019-07-08 | Juul Labs Inc | Fillable vaporizer cartridge and method of filling. |
BR112018016402B1 (en) | 2016-02-11 | 2023-12-19 | Juul Labs, Inc | SECURELY FIXED CARTRIDGES FOR VAPORIZER DEVICES |
US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
US20200037665A1 (en) | 2016-10-27 | 2020-02-06 | Mcneil Ab | A vapor generating device and a method for generating vapor |
GB201707769D0 (en) * | 2017-05-15 | 2017-06-28 | British American Tobacco Investments Ltd | Liquid tobacco extract |
GB201707758D0 (en) | 2017-05-15 | 2017-06-28 | British American Tobacco Investments Ltd | Ground tobacco composition |
JP2020525047A (en) * | 2017-06-26 | 2020-08-27 | ヌード ニコチン, インコーポレイテッドNude Nicotine, Inc. | Nicotine salt and method for producing and using the same |
USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
BR112020024276A2 (en) * | 2018-06-28 | 2021-02-23 | Philip Morris Products S.A. | cartridge for an aerosol generating system containing a nicotine source comprising a liquid nicotine formulation |
EP3855961B1 (en) | 2018-09-28 | 2023-05-17 | Philip Morris Products S.A. | Aerosol-generating system providing preferential evaporation of nicotine |
GB201817860D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolised formulation |
WO2020136061A1 (en) * | 2018-12-28 | 2020-07-02 | Philip Morris Products S.A. | High viscosity nicotine formulation |
JP2022516896A (en) | 2018-12-31 | 2022-03-03 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Low-viscosity liquid nicotine preparation |
US20220312827A1 (en) * | 2019-06-25 | 2022-10-06 | Philip Morris Products S.A. | Carbonated liquid nicotine formulation |
CN111227295A (en) * | 2020-01-20 | 2020-06-05 | 深圳梵活生命科学股份有限公司 | Smokeless electronic atomized liquid and preparation method thereof |
WO2021150856A1 (en) * | 2020-01-23 | 2021-07-29 | Myst Labs Inc. | Nicotine liquid formulation incorporating sugar esters for an electronic vaporization device |
CN111772226A (en) * | 2020-08-05 | 2020-10-16 | 四川三联新材料有限公司 | Method for improving comfort of heated cigarettes |
CN113912585B (en) * | 2021-11-09 | 2023-02-24 | 深圳萨特瓦生物科技有限公司 | Composite nicotine salt, preparation method and application thereof, electronic cigarette oil and electronic cigarette |
WO2023161465A1 (en) | 2022-02-28 | 2023-08-31 | Jt International S.A. | Provision of high nicotine aerosol |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2030862A (en) * | 1978-04-10 | 1980-04-16 | Smith A | A composition for treating drug addiction such as smoking nicotine-containing products |
ES2148549T3 (en) * | 1994-09-07 | 2000-10-16 | British American Tobacco Co | SMOKING ITEMS. |
CN100381083C (en) | 2003-04-29 | 2008-04-16 | 韩力 | Electronic nonflammable spraying cigarette |
WO2006082748A1 (en) * | 2005-02-02 | 2006-08-10 | Daicel Chemical Industries, Ltd. | Cigarette filter material and cigarette filter |
WO2007078273A1 (en) * | 2005-12-22 | 2007-07-12 | Augite Incorporation | No-tar electronic smoking utensils |
US7845359B2 (en) | 2007-03-22 | 2010-12-07 | Pierre Denain | Artificial smoke cigarette |
KR20100028182A (en) * | 2008-09-04 | 2010-03-12 | 고정현 | Nicotine composition |
GB2469842A (en) * | 2009-04-29 | 2010-11-03 | British American Tobacco Co | Aerosol generating material for a smoking article |
US9254002B2 (en) * | 2009-08-17 | 2016-02-09 | Chong Corporation | Tobacco solution for vaporized inhalation |
EP2340729A1 (en) * | 2009-12-30 | 2011-07-06 | Philip Morris Products S.A. | An improved heater for an electrically heated aerosol generating system |
ITMI20112290A1 (en) * | 2011-12-16 | 2013-06-17 | Dks Aromatic Srl | COMPOSITION FOR ELECTRONIC CIGARETTES |
US9078474B2 (en) | 2012-01-30 | 2015-07-14 | Spencer Thompson | Cartomizer for electronic cigarettes |
US10004259B2 (en) | 2012-06-28 | 2018-06-26 | Rai Strategic Holdings, Inc. | Reservoir and heater system for controllable delivery of multiple aerosolizable materials in an electronic smoking article |
US10117460B2 (en) * | 2012-10-08 | 2018-11-06 | Rai Strategic Holdings, Inc. | Electronic smoking article and associated method |
-
2015
- 2015-05-20 HR HRP20220075TT patent/HRP20220075T1/en unknown
- 2015-05-20 PL PL19199645T patent/PL3639813T3/en unknown
- 2015-05-20 EP EP19199645.3A patent/EP3639813B1/en active Active
- 2015-05-20 CA CA2949579A patent/CA2949579A1/en not_active Abandoned
- 2015-05-20 WO PCT/EP2015/061036 patent/WO2015177177A1/en active Application Filing
- 2015-05-20 RU RU2016149657A patent/RU2707079C2/en active
- 2015-05-20 AU AU2015261970A patent/AU2015261970A1/en not_active Abandoned
- 2015-05-20 CN CN201580027005.6A patent/CN106413697B/en active Active
- 2015-05-20 HU HUE19199645A patent/HUE057489T2/en unknown
- 2015-05-20 ES ES19199645T patent/ES2906209T3/en active Active
- 2015-05-20 JP JP2016568668A patent/JP6529990B2/en active Active
- 2015-05-20 US US15/311,212 patent/US20170079319A1/en not_active Abandoned
- 2015-05-20 LT LTEP19199645.3T patent/LT3639813T/en unknown
- 2015-05-20 MX MX2016015179A patent/MX2016015179A/en active IP Right Grant
- 2015-05-20 PT PT191996453T patent/PT3639813T/en unknown
- 2015-05-20 KR KR1020167035350A patent/KR102456728B1/en active IP Right Grant
- 2015-05-20 EP EP15722728.1A patent/EP3145492A1/en not_active Withdrawn
- 2015-05-20 DK DK19199645.3T patent/DK3639813T3/en active
-
2016
- 2016-11-09 IL IL248867A patent/IL248867B/en active IP Right Grant
-
2019
- 2019-07-25 US US16/521,943 patent/US20190343169A1/en not_active Abandoned
-
2020
- 2020-06-29 AU AU2020204342A patent/AU2020204342B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12016366B2 (en) | 2019-06-07 | 2024-06-25 | Philip Morris Products S.A. | Nicotine pouch composition and pouch comprising such |
Also Published As
Publication number | Publication date |
---|---|
KR20170007443A (en) | 2017-01-18 |
CN106413697B (en) | 2020-05-15 |
PL3639813T3 (en) | 2022-04-19 |
LT3639813T (en) | 2022-04-11 |
AU2020204342A1 (en) | 2020-07-16 |
PT3639813T (en) | 2022-03-01 |
DK3639813T3 (en) | 2022-03-07 |
ES2906209T3 (en) | 2022-04-13 |
US20170079319A1 (en) | 2017-03-23 |
EP3639813B1 (en) | 2022-01-12 |
RU2016149657A3 (en) | 2019-01-23 |
JP2017518289A (en) | 2017-07-06 |
HUE057489T2 (en) | 2022-05-28 |
RU2707079C2 (en) | 2019-11-22 |
IL248867B (en) | 2020-10-29 |
EP3639813A1 (en) | 2020-04-22 |
EP3145492A1 (en) | 2017-03-29 |
KR102456728B1 (en) | 2022-10-21 |
RU2016149657A (en) | 2018-06-21 |
AU2020204342B2 (en) | 2022-06-30 |
US20190343169A1 (en) | 2019-11-14 |
AU2015261970A1 (en) | 2016-12-01 |
HRP20220075T1 (en) | 2022-04-15 |
CN106413697A (en) | 2017-02-15 |
WO2015177177A1 (en) | 2015-11-26 |
IL248867A0 (en) | 2017-01-31 |
MX2016015179A (en) | 2017-06-30 |
JP6529990B2 (en) | 2019-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020204342B2 (en) | A liquid formulation comprising nicotine for aerosol administration | |
CN104768406B (en) | nicotine composition | |
EP3214956B1 (en) | Solution comprising nicotine in unprotonated form and protonated form | |
KR102665932B1 (en) | Nicotine liquid formulations for aerosol devices and methods thereof | |
BR112020024088A2 (en) | nicotine formulation | |
US9380810B2 (en) | Tobacco-based nicotine aerosol generation system | |
Werley et al. | Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs | |
BR112012005972A2 (en) | improved device and method for dispensing a drug | |
US20060018840A1 (en) | Aerosolizable formulation comprising nicotine | |
WO2016133890A1 (en) | Compositions for e-cigarettes | |
WO2020239083A1 (en) | Aerosol generation or smoking system, or electronic cigarette and device thereof | |
Armitage et al. | The effect of inhalation volume and breath-hold duration on the retention of nicotine and solanesol in the human respiratory tract and on subsequent plasma nicotine concentrations during cigarette smoking | |
CA2953285A1 (en) | Nicotine dosage regimen | |
JP2018016658A (en) | Novel propellant-containing preparations for tiotropium | |
US20150374034A1 (en) | Nicotine Dosage Regimen | |
WO2020160667A1 (en) | Nicotine aerosol formulation | |
Hosseini et al. | Effects of device settings and e-liquid characteristics on mouth-throat losses of nicotine delivered with electronic nicotine delivery systems (ENDS) | |
Naji | Vape as Another Drug Delivery System | |
KR20030055457A (en) | Aerosol for helping quit smoking |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200519 |
|
FZDE | Discontinued |
Effective date: 20221018 |
|
FZDE | Discontinued |
Effective date: 20221018 |